OUR PORTFOLIO

Our portfolio includes grants and mission-related investments supporting Alzheimer’s drugs in development, biomarkers, prevention programs, and other projects designed to build the capacity of the field. You can explore the programs we have supported using the filter and “Search Database” options in the sidebar.

All Filters

Clear
Clear
Clear
Clear
Clear
Clear
Clear
Investigator: Ronald van der Geest

2 Projects | 1 Researchers | $5,137,143 Invested

2022

Treeway B.V.

Ronald van der Geest, PhD

A Phase II Study to Determine the Preliminary Efficacy and Safety of Oral Edaravone (TW001) in Alzheimer Patient - Extension

  • Funding Amount: $2,143,020
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Oxidative Stress
  • Status: Active

2018

Treeway B.V.

Ronald van der Geest, PhD

A Phase IIa Trial to Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of TW001 in Alzheimer Patients

  • Funding Amount: $2,994,123
  • Organization Type: Biotechnology/For Profit
  • Program: Clinical
  • Target: Oxidative Stress
  • Status: Active